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Growth Factors in Human Disease: The Realities, Pitfalls, 
and Promise 
By C. William Castor and Antonio R. Cabral 
T HE LITERATURE related to growth fac- tors increases at such a rapid rate that the 
cynical might postulate factors governing the 
development of new growth factors. In an effort 
to put a manageable perimeter around the sub- 
ject, this review focuses primary attention on 
well characterized growth factors, known or sus- 
pected to exist in man. 
While a universally accepted definition of a 
growth factor does not exist, usage accepts 
growth factors as relatively small proteins that 
induce increased cell synthesis of nucleic acids, 
protein, and increased cellular mass. Conven- 
tionally, growth factors are considered to be 
agents with mitogenic activity. However, in con- 
nective tissues where a disproportionately small 
number of cells participate in the formation of a 
large extracellular matrix, growth may be mani- 
fested not only by increased cell numbers, but 
also by increases in one or several components of 
the extracellular matrix. The physiologic import 
of this distinction is not trivial when one recalls 
that approximately 75% of the human body is of 
mesenchymal origin, and that skeletal tissues, 
skin, and fascia (excluding muscular compo- 
nents) account for >33% of the body mass.‘** 
Also, it is pertinent to note that one of the first 
known growth factors, sulfation factor, was mea- 
sured by its growth promoting activity as judged 
by the increased sulfated glycosaminoglycan 
(GAG) content of cartilage extracellular matrix. 
Sulfation factor was subsequently shown to be 
several proteins constituting a group of human 
growth hormone dependent proteins, members of 
the somatomedin family; knowledge of their 
mitogenic properties was a later development. 
The same principle applies to epithelial tis- 
sues; for example, epidermal growth factor 
(EGF) stimulates not only replication of cells, 
but formation of extracellular material such as 
keratin. Similarly, connective tissue cells exposed 
to EGF respond with both increased cell replica- 
tion and increased synthesis and secretion of 
hyaluronic acid, an extracellular matrix compo- 
nent. 
Although the notion of growth promotion 
evokes the impression that growth factors are 
primarily concerned with anabolic events, it may 
be wise to visualize growth as a net increment in 
cells and certain of their extracellular products. 
Some growth factors also promote events whose 
primary impact is catabolic; connective tissue 
activating peptide- (CTAP-III), primarily 
known for its mitogenic and GAG stimulating 
properties, also stimulates synthesis and se- 
cretion of a degradative protease, plasminogen 
activator.3 Similarly, interleukin- 1 (Il- 1). a 
potent stimulator of anabolic processes, also pro- 
motes synthesis and secretion of collagenase and 
prostaglandins by many types of sensitive cells. It 
seems likely that some growth factors evoke both 
anabolic and catabolic behavior by a single cell. 
The mechanism(s) for organized integration of 
these opposing metabolic vectors in intact organ- 
isms will be a focus of investigative effort in the 
future. 
Earlier debate aimed at classifying growth 
factors as hormones or autacoids now seems 
moot in the face of new data and the recognition 
of the depth of our ignorance. For instance, it 
seems likely that the several growth factors 
released from platelet alpha granules after plate- 
let aggregation exert a potent local effect, thus 
behaving as autacoid mediators. Yet, there are 
no data to rule out significant distant (hormonal) 
biological effects from these substances, at least 
some of which are found in plasma. In the case of 
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the insulin-like growth factors (IGF-I and IGF- 
II) both the site(s) of origin and action are 
uncertain! 
METHODS FOR DETECTING AND MEASURING 
GROWTH FACTORS 
Bioassay is the initial technique for detecting 
and measuring a growth factor; it requires dis- 
covery of a factor dependent event in whole 
animals, tissue fragments, or cultures. Nerve 
growth factor (NGF), for instance, was shown to 
enhance the growth of sympathetic ganglia in 
vitro and to elicit neurite outgrowth from 
embryonic sympathetic and sensory ganglia 
explanted in vitro.4 In a more exotic vein, frac- 
tions containing EGF injected into newborn mice 
caused precocious opening of the eyelids and 
premature eruption of the incisors, thus forming 
the basis of a bioassay.’ Observations of this 
nature provide investigators with the initial 
assays that permit protein fractionation studies 
aimed at isolating the responsible agent(s). 
approach derive from the fact that crude mix- 
tures may contain several components able to 
stimulate a responsive cell system, or may 
include inhibitors able to modify the cellular 
responsiveness in a misleading fashion in the 
opposite direction. Nonetheless, the bioassay is 
necessarily the guide for investigators attempting 
to isolate highly purified principles from crude 
mixtures by protein fractionation techniques. 
A different, and sometimes more quantitative, 
dimension was added to the study of growth 
factors when investigators examined selected 
specific effects of these agents, commonly using 
tactics to measure cell replication or increased 
DNA synthesis. Alternatively, one may measure 
increased synthesis of extracellular matrix com- 
ponents (eg, glycosaminoglycans, proteoglycans, 
collagen, keratin) using appropriate isotopic or 
chemical methodology. Weaknesses of this 
Isolation (guided by bioassay) of a growth 
factor in a homogeneous form opens many new 
doors. The purified material may be used to 
develop antisera useful for detection of the factor 
by immunodiffusion, its measurement by radial 
immunodiffusion (RID), radioimmunoassay 
(RIA), or enzyme linked immunoassay 
(ELISA). Alternatively, the availability of the 
purified growth factor may allow preparation of 
a radiolabeled conjugate so that it may be 
detected and measured in membrane receptor 
assays. Immunologic methods, however, may fail 
to distinguish between active and inactive forms 
of a particular molecule, in addition to possible 
problems related to cross reactivity; radiorecep- 
tor assays may also on occasion give rise to 
nonspecific results. 
WELL DEFINED HUMAN GROWTH FACTORS 
A partial list of well defined growth factors 
that may have biological importance in humans 
is shown in Table 1. 
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Possible Clincal Significance 
Wound healing, neurofibromatosis 
Inflammation, wound healing, athero- 
sclerosis, neoplasla 
Inflammation, would healing, athero- 
sclerosis, neoplasia 
Leprechaunism, mediates hGH actton 
Mediates hGH action 
Mediates immune responses, connec- 
twe tissue growth and wound heal- 
ing. An endogenous pyrogen 
Maintenance of sympathetic nervous 
system. neural neoplasm% Alz- 
heimer disease 
Wound healing, inflammation 
Unclear 
GROWTH FACTORS IN HUMAN DISEASE 
EGF-Urogastrone 
EGF was first described in the mouse submax- 
illary gland and later isolated from human urine 
(as urogastrone).6 Computer based studies indi- 
cate that the precursor of mouse EGF (mEGF) 
has substantial similarity to bovine factor X, 
data supporting the concept that EGF arose 
early in vertebrate species.’ New evidence local- 
izing an EGF-like material in the human platelet 
alpha granule argues that it may be synthesized 
by megakaryocytes in humans.* Aspects of the 
discovery, isolation, and mechanism of action of 
EGF have been summarized.g*‘O EGF from 
mouse submaxillary gland and human urine is a 
heat stable acidic polypeptide chain; it has been 
sequenced and shown to have 53 amino acid 
residues and three intramolecular disulfide 
bonds. Synthesized and stored in the subman- 
dibular gland, mEGF is found in granular form 
in convoluted tubules. 
In vivo, EGF stimulates cell proliferation, 
keratinization, premature eruption of incisors 
and inhibits gastric acid secretion. Merino sheep, 
infused with EGF, showed temporary cessation 
of follicular activity, and wool protein became 
abnormal.” Palatogenesis during embryonic 
development may be controlled in part by EGF; 
the presumed mechanism involves increased con- 
centration of environmental hyaluronic acid, 
thought to be critical for palatal shelf elevation 
and/or fusion of medial epithelium.” 
In vitro actions of EGF-urogastrone include 
stimulation of cell proliferation in many types of 
epithelial and fibroblastic cells. EGF induces 
increased synthesis of DNA, RNA, cyclic 
nucleotides, and enhanced transport of nutri- 
tional precursors. In appropriate cell types, EGF 
stimulates synthesis and secretion of specialized 
proteins (as prolactin or collagen) and complex 
carbohydrates (as hyaluronic acid). EGF 
induced stimulation of prolactin synthesis in rat 
pituitary celis apparently depends on accelerated 
transcription of the prolactin gene.13 Although 
mEGF caused selective dose dependent synthesis 
of collagen fibers by rat liver epithelial cells,14 it 
had little effect on collagen formation in cultures 
of rat liver fibroblasts” and reduced collagen 
synthesis in mouse osteoblastic cultures.‘6 Such 
data emphasize and ambiguities in growth factor 
bioassays that may result from the choice of 
species or tissue type used to serve as a target 
system. 
Binding of EGF to specific fibroblast receptors 
is irreversible; it is followed by phosphorylation 
of the receptors, internalization, and proteolytic 
processing in lysosomes. Remodeled receptor 
fragments may serve as intracellular signals for 
the multiple specific actions attributed to EGF.” 
The gene coding for the human EGF receptor is 
believed to reside on chromosome No. 7.” Pep- 
tides derived from the receptor protein show a 
high degree of homology with the deduced 
sequence of the v-erb-B transforming protein of 
the avian erythroblastosis virus.” Retrovirus 
transformed rat fibroblasts have been shown to 
synthesize and secrete a transforming growth 
factor type I (rTGF-I, also, rTGFcu) that shows 
substantial sequence homology with the mEGF- 
urogastrone family and shares the same biologi- 
cal activities.20 TGF-& said to be present in 
normal cells and stored in platelets, is unrelated 
to EGF structurally or functionally, but regu- 
lates the number of receptors for EGF in certain 
cell types.” Monoclonal antibodies against the 
EGF receptor protein induce some of the effects 
of EGF itself, including stimulation of thymidine 
incorporation into DNA. This observation sup- 
ports the concept that information in the EGF- 
membrane receptor system resides primarily in 
the membrane receptor itself.22 
Recently, a chemically synthesized gene for 
hEGF was expressed in yeast; the resultant bio- 
synthetic hEGF was shown to compete with 
“‘1-mEGF in a receptor binding assay using 
human dermal fibroblast plasma membranes23 
and was reported to elicit precocious eyelid open- 
ing, incisor eruption, and inhibition of gastric 
secretion. Although this study yielded small 
quantities of hEGF, the methodology has poten- 
tial for providing large enough amounts of this 
protein to permit full exploration of its many 
possible biological and medical applications. For 
instance, topically applied EGF has been 
reported to promote healing of cornea1 ulcers.24 
Physiologic control of EGF as well as the 
pathophysiologic roles of this peptide are yet 
dimly lit arenas. In the mouse, EGF is known to 
be regulated by androgens; recent evidence indi- 
cates that thyroid hormones and adrenocortical 
hormones also regulate EGF in this species.2’ In 
senescent mice, the submandibular glands appar- 
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ently contain decreased amounts of EGF.26 Bind- 
ing sites for EGF in skin fibroblasts from patients 
with neurofibromatosis were greatly diminished 
compared with age and passage matched normal 
strains.” 
Platelet Factors 
It is clear that human platelets contain both 
cationic and anionic growth factors; one labora- 
tory reported three different forms.2s Current 
interest centers on four classes of growth promot- 
ing proteins, cationic proteins such as connective 
tissue activating peptide- (CTAP-III) and the 
several molecular forms of platelet derived 
growth factors (PDGF), and anionic platelet 
derived growth factors including CTAP-P, and 
possibly EGF. 
Connective Tissue Activating Peptide-III 
This thrombin releasable growth promoting 
factor in human platelets has been isolated and 
studied in detai1.29,30 CTAP-III, isolated from 
both fresh and outdated human platelets, is a 
9,278-dalton single chain protein with an aver- 
age isoelectric point of 8.5.3’ Recent data show 
isoelectric point related microheterogeneity that 
modifies growth factor activity. Amino acid 
sequence and immunologic studies demonstrate 
that CTAP-III differs from fl-thromboglobulin 
(fi-TG) by an additional amino terminal tetra- 
peptide.3’“2 Proteolytic removal of the amino 
terminal tetrapeptide degrades CTAP-III to fl- 
TG and obliterates growth factor activity. 
Growth factor activity, as measured by enhanced 
DNA or GAG synthesis in human fibroblast 
cultures, also depends on the intact status of one 
or both of the two intrachain disulfide bonds. 
Specific antisera directed against CTAP-III 
resulted in immunoprecipitation and loss of 
mitogenic activity from solution. 
Depending on the characteristics of the prepa- 
ration, nanogram to microgram quantities of 
CTAP-III stimulate synthesis of DNA, hyal- 
uranic acid, sulfated GAG chains, proteoglycan 
monomer, and proteoglycan core protein in 
human fibroblast cultures. CTAP-III also stimu- 
lates glucose transport, formation of prostaglan- 
din E,, hyaluronic acid synthetase activity, and 
the synthesis and secretion of plasminogen acti- 
vator. 
Elevated plasma CTAP-III levels have been 
demonstrated by radioimmunoassay in rheuma- 
toid arthritis, systemic lupus, and other forms of 
vasculitis and appeared to parallel clinical dis- 
ease activity,33,34 suggesting a possible pathoge- 
netic role for CTAP-III. CTAP-III antigen and 
biological activity were found in platelets of 
growth hormone deficient children, indicating 
that CTAP-III is not human growth hormone 
dependent.” 
Connective Tissue Activating Peptide-P, 
(CTAP-P,) 
CTAP-P, is an anionic platelet factor36,37 and 
like CTAP-III, CTAP-P, is a potent mitogen for 
synovial, cartilage, lung, and skin fibroblasts and 
stimulates hyaluronate and sulfated GAG for- 
mation in these cell cultures. Unlike CTAP-III 
and PDGF, CTAP-P, has an acidic p1 (approxi- 
mately 4.5) with an apparent molecular weight 
of 19,000 daltons. It has been separated from 
albumin by immunoaffinity chromatography, 
and shown to be immunologically different from 
CTAP-III. CTAP-P, does not compete with 
EGF in radioreceptor assays (M.D. Hollenberg 
and D.N. Orth, personal communications, 
1984). 
Platelet Derived Growth Factor(s) (PDGF) 
Preparations have been interpreted to suggest 
that PDGF is a molecule with two disulfide 
linked chains, each with a molecular weight of 
14,000 to 16,000 daltons3* PDGF is generally 
believed to exist in two forms: PDGF-I and 
PDGF-II whose molecular weights are 3 1,000 
and 28,000 daltons, respectively.39 Differences in 
glycosylation lead some to postulate four molecu- 
lar forms of PDGF.40 Preliminary sequence stud- 
ies of PDGF show no resemblance to CTAP- 
II1.4’ Of considerable interest are two reports 
suggesting that a transforming protein from sim- 
ian sarcoma virus and one PDGF peptide chain 
are so closely related as to indicate that they are 
derived from the same or closely related 
genes.42,43 
Partially purified PDGF modified lipid 
metabolism by enhancing cholesterol synthesis 
and increasing the number of LDL receptors in 
monkey aortic muscle cells.44 It now appears that 
PDGF is capable of stimulating cell division 
without the need for progression factors in plas- 
ma.45 PDGF is chemotactic for fibroblasts and 
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vascular smooth muscle cells;46 another study 
showed that three platelet alpha granule pro- 
teins, platelet factor 4, /!I-TG, and PDGF each 
exhibited chemotactic activity for human skin 
fibroblasts!’ Studies of PDGF interactions with 
fibroblast receptors suggest that PDGF and EGF 
are not processed via a common pathway.48 
Epidermal Growth Factor 
EGF must be considered as a possible platelet 
derived anionic growth factor on the basis of 
radioimmunoassay and radioreceptor assay data; 
it appears to be located in the platelet alpha 
granules and is released during blood coagula- 
tion.” In addition to the human platelet derived 
growth factors, recent reports suggest that 
human platelets contain an endothelial cell 
growth factor49 and a transforming growth factor 
(TGF).” The relationship of platelet EGF to 
platelet TGF is unclear. Further purification and 
characterization of these materials will deter- 
mine whether they are distinct from the better 
defined platelet derived factors. Thus, it appears 
that platelets may carry two anionic (EGF and 
CTAP-P2) and two cationic (CTAP-III and 
PDGF) thrombin extrudable factors that are 
immunologically and structurally distinct. It is 
not known whether they are derived from a 
common larger protein or whether they are syn- 
thesized as completely separate entities. 
Insulin-Like Growth Factors (ZGA, Z, ZZ) and 
Somatomedins 
Radioimmunoassay methods that specifically 
recognized insulin demonstrated that only 7% of 
the insulin-like activity of serum was insulin (and 
consequently suppressible by antiinsulin serum); 
the remainder was originally designated as non- 
suppressible insulin-like activity (NSILA). The 
NSILA material(s) are themselves growth hor- 
mone dependent, and in turn have growth pro- 
moting activity in chick embryo fibroblast cul- 
tures and in several other systems. NSILA has 
now been resolved into two entities: insulin-like 
growth factors I and II (IGF-I, IGF-II) whose 
covalent structures are known.51 IGF-I is a single 
chain containing 70 residues (7,649 daltons) 
with three disulfide bonds; it exhibits marked 
homology with proinsulin.51V52 IGF-II is a 7,471 
dalton protein with three intrachain disulfide 
bonds, and it shows substantial homology with 
both IGF-I and proinsulin. 
Both IGF-I and IGF-II stimulate DNA syn- 
thesis in chick embryonic tissue and 35S04 uptake 
in rat costal cartilage;53 both IGF species also 
promote mitosis in rabbit lens epithelial cells.54 
In skeletal muscle, fat, and heart cells, IGF 
stimulated 2-deoxyglucose (2-dG) uptake, pre- 
sumably not acting through the insulin receptor. 
Although IGF was 50 to 100 times more potent 
than insulin with respect to growth parameters, it 
was only l/60 as potent as insulin in stimulating 
2-dG uptake by fat cells.” 
Radioimmunoassay and radioreceptor assays 
suggested that IGF-I was related to somatome- 
din C (SM-C);S6 recent amino acid sequence 
analysis of purified SM-C now confirms the 
identity of SM-C and IGF-I.” Skin fibroblasts 
were shown by radioimmunoassay to secrete 
material resembling SM-C; secretion was 
blocked by cycloheximide and stimulated by 
hGH (human growth hormone), platelet derived 
growth factors and fibroblast growth factor 
(FGF), but not by EGF, thyroxine, or cortisol.” 
Parenteral injection of ovine growth hormone 
into hypophysectomized rats resulted in in- 
creased tissue extractable IGF-1 /SM-C from 
kidney, heart, liver, lung, and testes; these data 
support the concept of multiple sites of synthesis 
coupled with a local site of action.59 
Radioimmunoassay of IGF-I and IGF-II show 
IGF-I levels to be elevated in acromegaly and 
depressed in hGH deficiency. Enhanced se- 
cretion of IGF-II with acromegaly is not seen; 
however, the values are low in hGH deficiency, 
supporting the belief that both factors are growth 
hormone dependent. Extra pancreatic tumors 
associated with hypoglycemia were not asso- 
ciated with increased levels of IGF-I and IGF- 
IL60 Leprechaunism, a syndrome characterized 
by growth retardation, poor muscle development, 
and absence of fat, may result from deficiency of 
insulin-like growth factor activity. Some patients 
with this syndrome were reported deficient in 
cellular receptors for IGF-L6’ The demonstration 
that synthetic IGF-l/SM-C has biological and 
immunologic properties identical to the natural 
product should facilitate the testing of these 
materials in relevant clinical contexts.62 
Growth hormone affects cartilage by inducing 
the formation of secondary substances, soma- 
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tomedins (formerly, sulfation factors), which in 
turn interact with chondrocytes to modify their 
metabolism. Somatomedins in serum stimulate 
3sS0, uptake by cartilage from hypophysecto- 
mized rats; serum from hypophysectomized rats 
is less stimulatory than that from normal rats, 
and administration of growth hormone restored 
stimulatory activity to the serum of hypophysec- 
tomized animals. 63 Bioassay of somatomedins in 
human serum disclosed high activity levels in 
acromegaly; lower levels were found after hypo- 
physectomy and in patients with pituitary dwarf- 
ism. hGF injected into hypophysectomized 
patients or pituitary dwarfs restores human 
somatomedin levels to the normal range. 
At least three somatomedins (A, B, and C) 
were thought to be present in human plasma; 
somatomedin A (SM-A) isolated from human 
plasma has a molecular weight of approximately 
7,000 with asparagine at its N-terminus. SM-A 
stimulates incorporation of ‘SO, into GAG in 
chick cartilage and DNA synthesis in both chick 
embryo and human fibroblasts.64 Somatomedin 
B (SM-B) stimulated DNA synthesis in human 
glial cells and human embryonic lung fibro- 
blasts.‘j5 Purification of SM-C from human 
plasma led to proof that it is identical to IGF-I. 
Although IGF-I and IGF-II bind to multiplica- 
tion stimulation activity (MSA) receptors, it 
may not mean that IGF and MSA are identical; 
the data may suggest multiple types of receptors 
for IGF materials.66 One review characterized 
MSA as a rat plasma somatomedin that shares 
properties with IGF-I, IGF-II, and insulin.67 
Interleukin 1 
IL-l, the first well defined human monokine, 
was originally known as lymphocyte activating 
factor (LAF). It is a potent mitogen for mouse 
thymocytes and may be an important mediator 
of inflammation in humans, possibly also acting 
as an endogenous pyrogen.68V69 IL-1 is secreted by 
activated macrophages of human and mouse and 
by large granular human lymphocytes.70 Synthe- 
sis of IL-1 may also be triggered by a cell contact 
dependent process involving activated lympho- 
cytes, and promoted by endotoxins and phagocy- 
tosis. IL-1 stimulates helper T cell release of 
IL-2, a T cell growth factor. IL-1 not only has a 
role in promoting T cell proliferation, but it 
modifies in vitro immune responses and induces 
incremental PGEz and collagenase synthesis and 
secretion by human synovial cells.7’~73 Both the 
murine and human form of IL-1 have been 
purified to near homogeneity;68.74 human IL-1 is 
heat labile and stable to acid and thiols, and has a 
molecular weight of 11,000 to 15,000 daltons 
with an isoelectric point near 7.1. 
In addition to the many immunologically 
oriented activities of IL- 1, recent studies indicate 
that this peptide stimulates DNA synthesis in 
normal human connective tissue cells and pro- 
motes formation of major extracellular matrix 
components, including collagen and glycosami- 
noglycans. Its high specific activity makes this 
molecule a candidate for major roles in the 
inflammatory process. 
Connective Tissue Activating Peptide-Urine 
(CTAP-U) 
CTAP-U is a 16 to 30 kilodalton peptide 
isolated from human urine75 that stimulates 
DNA, hyaluronate, and sulfated GAG formation 
in skin, synovial, and cartilage fibroblast cul- 
tures. Proteolytic digestion destroys its growth 
factor activity, but biological activity is unaf- 
fected by thiol, acid, or heat treatment. Both ion 
exchange chromatography and preparative iso- 
electric focusing define two major areas of activ- 
ity in the ranges of pH 2 to 3 and pH 4 to 5. 
Whether this represents two or more different 
growth factors or microheterogeneity of one ago- 
nist is unclear. CTAP-U does not compete in 
radioreceptor assays with insulin, basic soma- 
tomedin, or EGF and is immunologically distinct 
from CTAP-III, CTAP-P,, IgG, and its Fc and 
Fab fragments. Little is known about the origin 
of this peptide( It could represent urinary tract 
associated autacoid(s) or metabolite(s) of growth 
or nongrowth factor protein(s). 
CTAP-PMN 
A human granulocyte derived factor that stim- 
ulates DNA and GAG synthesis by human fibro- 
blasts, CTAP-PMN is relatively heat stable, 
sensitive to thiols, and has a molecular weight 
between 12,700 and 15,700 daltons. This factor 
might play a role in chronic proliferative synovi- 
tis or in other settings where exudative inflam- 
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mation is accompanied by connective tissue 
growth.76 
Nerve Growth Factor (NGF) 
Although present in many tissues, NGF is 
found in high concentrations in some snake 
venoms and in the male mouse submaxillary 
gland.” It elicits overgrowth of sympathetic 
chain ganglia in vivo and promotes halo-like 
outgrowth of nerve fibers from embryonic sym- 
pathetic ganglia cultured in vitro. NGF may be 
important in regulation of neural cell growth and 
differentiation and may contribute to the sur- 
vival of peripheral sympathetic and spinal sen- 
sory neurons. 
NGF isolated from the mouse submaxillary 
gland is a hexameric 140,000 dalton protein 
complex composed of a, @, and y subunits. The LX 
subunit subserves a regulatory function, the y 
subunit is an arginine esteropeptidase, and the 
biological activity resides in the p subunit.78 The 
/3 subunit of NGF (/3NGF) has been sequenced; 
the primary peptide has a molecular weight of 
13,259 daltons and associates in two subunits 
with a molecular weight of 26,518 daltons. 
@NGF has three disulfide bonds, and the many 
acidic residues present in the amide form may 
account for its basic nature. The biological activ- 
ity of PNGF is inhibited in the hexameric com- 
plex; this in turn protects the active component 
from proteolysis. 
Administration of antibodies to NGF to ani- 
mals causes total destruction of the sympathetic 
nervous system. NGF may be viewed as a hor- 
mone capable of positive pleiotropic stimulation 
of developing nerve tissue, and may be required 
in small amounts to maintain a mature sympa- 
thetic nervous system. NGF activity immunolog- 
ically identical to that of submaxillary glands has 
been found in blood and other peripheral organs. 
Structural similarities between NGF and proin- 
sulin lead to the suggestion that NGF is related 
in an evolutionary sense to a primitive form of 
proinsulin. 
There are few unambiguous data confirming 
the presence of NGF in human tissues. A recent 
review emphasizes the possible role of nerve 
growth factor in human neoplasms including 
sarcoma, neuroblastoma, and gliomas.” Older 
data suggested that NGF was secreted by a 
human glioblastoma cell strain.*’ Further, 
human melanoma cells in culture were shown by 
indirect immunofluorescence to possess surface 
NGF; NGF receptors were thought to be present 
on the basis of both immunofluorescence and 
“‘1-NGF binding. *2 A highly purified receptor 
for NGF has also been prepared from mem- 
branes of a human melanoma cell line by affinity 
chromatography.83 
The similarity of physiologic deficits in Alz- 
heimer disease and some functions subserved by 
NGF led to speculation that this malady may be 
caused either by a deficiency of NGF or 
decreased responsiveness of cholinergic neurons 
to NGF.84 Other lines of evidence indicate that 
NGF is chemotactic for human leukocytes in 
vitro at concentrations similar to those that stim- 
ulate neurite outgrowth,*’ suggesting that this 
peptide may normally modulate nonneural cell 
function, possibly playing a role in wound 
repair. 
GROWTH FACTORS AND NEOPLASIA 
The fundamental observation that tumor cells 
conserve the transformed phenotype and that 
neoplastic transformation may be the result of 
genetic alteration has important consequences, 
among others, the ability of malignant cells to 
produce growth factors capable of lowering or 
replacing their serum requirements during pro- 
pagation in vitro.86 
The concept of neoplastic transformation is 
being expanded by study of retroviruses, whose 
presence is thought to be required to initiate and 
maintain viral transformations7 The viral trans- 
forming agents, termed oncogenes, are recog- 
nized in vertebrate cellular genes (c-one)** and 
can be actively transcribed.89 It is believed that 
they were integrated into the viral genome dur- 
ing vertebrate infection,W and because these pro- 
tooncogenes are closely conserved during evolu- 
tion, it is supposed that their normal function is 
related to the regulation of cell replication and/ 
or differentiation.” 
One of the acute transforming retroviruses of 
primate origin is the simian sarcoma virus 
(SSV).9’ Its genome arose by recombination of 
simian associated virus with a segment derived 
from a woolly monkey cellular gene (v-sis).92 The 
entire genomic nucleotide sequence has been 
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reported,93 the transforming gene product has 
been identified (p28”“),9’ and the human homo- 
logue (c-sis) has been localized in chromosome 
22,94 with 93% nucleotide sequence homology 
between c-sis and v-sis.95,94 
Recently, two different laboratories42.43 inde- 
pendently concluded that a segment of the pre- 
dicted amino acid sequence of ~28”” has identical 
structural homology (87.1%) with the known 
amino terminal amino acid sequence of one of the 
PDGF chains.42,95 Subsequently, it was found 
that lysates of SSV transformed NIH-3T3 cells 
contain a growth factor that is identical to PDGF 
in immunoassay and has a mitogenic activity 
that is absent in nontransformed control cell 
lysates. This PDGF-like material has a different 
molecular weight (20,000 daltons) in SDS gels 
after immunoprecipitation with anti-PDGF anti- 
serum; it is supposed that this represents the 
degraded product of ~28”‘*.~’ These findings raise 
interesting questions in view of the fact that ~20”‘” 
is not secreted9’ and that PDGF by itself does not 
induce neoplastic transformation.98 
A recent report” indicated that the predicted 
v-erb-B transforming protein amino acid 
sequence closely resembles the partially known 
sequence of the transmembrane and the cyto- 
plasmic kinase domains of EGF receptor. Inter- 
estingly, it appears that the avian erythroblasto- 
sis virus carries in its genome the encoding 
sequences of an abnormal EGF receptor that 
lacks its binding region, perhaps leading to con- 
stant generation of a signal similar to that pro- 
duced by EGF, with subsequent rapid and auton- 
omous cell proliferation.‘9*99 There is evidence 
that other growth factor receptors besides EGF, 
including PDGF, insulin, and IGF-I have tyro- 
sine kinase activity, along with the recognition 
that other encoded oncogene products (such as 
pp60’“‘C, P9OWYe”, P85gag-fes) have this kind of 
enzymatic activity.‘@I Some are structurally 
related to the bovine CAMP dependent protein 
kinase catalytic chain,“’ providing further sup- 
port for the notion that transformation might 
occur as a result of alteration(s) at multiple 
points along the mitogenic pathway. It is possi- 
ble, then, that more than one signal is needed to 
induce oncogenic cell behavior. Perhaps several 
oncogenes act in concert and the action of one 
controls another, enhancing, inducing, or alter- 
ing the expression of a normal or defective 
growth factor cascade and/or its receptors.“* 
This would be expected not only to modulate cell 
replication, but also the synthesis and secretion 
of a myriad of proteins that in turn modulate 
gene expression. 
GROWTH FACTORS AND THE 
INFLAMMATORY PROCESS 
Fifteen years ago, studies in cell to cell com- 
munication were initiated by adding leukocytes 
or thrombocytes to synovial membrane derived 
connective tissue cells in monolayer cultures to 
simulate the mixed cell population found in 
rheumatoid synovium. Soluble factors from both 
intact and lysed lymphocytes, PMN leukocytes, 
and platelets were shown to activate synovial 
fibroblasts by greatly stimulating glucose con- 
sumption and connective tissue matrix forma- 
tion, particularly hyaluronic acid; further, the 
platelets stimulated cell replication.‘03,‘04 Subse- 
quently, many more protein mediators have been 
identified and reviewed.“’ 
Circumstantial evidence suggests that many 01 
the known growth factors are reasonable candi- 
dates to play roles in acute and chronic inflam- 
matory processes. Most of the better defined 
growth factors in man are associated with plate- 
lets, polymorphonuclear cells, lymphocytes, 
monocytes, or connective tissue cells--all cellu- 
lar elements well represented during the early 
and later stages of the inflammatory process. As 
shown in Fig 1, many factors exhibit anabolic or 
catabolic actions (or both); some seem to play a 
role in differentiation (EGF, in vivo studies) and 
several appear to have chemotactic activity that 
may be important in spatial positioning of cells. 
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How does one explain so many factors with many 
overlapping functions? Are some of in vivo 
importance and others bioassay artifacts? Is 
something gained by their acting in concert, in 
different combinations or sequences? A partial 
list of types of information that would help to 
resolve these questions is shown in Fig 1. Sensi- 
tive specific immunologic methods permitting 
sequential measurement of concentrations and 
locations of multiple factors during the course of 
well defined pathologic processes would help put 
these agents into a realistic perspective. The 
powerful impact of growth factors and the onco- 
gene concept on thinking about the pathogenesis 
of neoplasia may have an important counterpart 
in relation to the chronic inflammatory process, 
which is also characterized by self perpetuation, 
abnormal cell function, proliferation, and tissue 
destruction. 
COMMENTS 
The preceding sections have alluded to possi- 
ble roles for various growth factors in normal 
growth and differentiation, and in the pathogen- 
esis of acute and chronic inflammation, athero- 
sclerosis, wound healing, neoplasia, and certain 
degenerative diseases. We may expect that the 
short term future will see the application of 
quantitative immunoassay and receptor assay 
techniques to the diagnosis and management of 
such diseases. Further, it is likely that some 
growth factors will be available in bulk quanti- 
ties, either via direct chemical synthesis or by 
way of recombinant DNA technology; this will 
provide an opportunity to test such agents as 
therapeutic modalities on problems such as non- 
healing wounds. When the actions of growth 
factors in health and disease are precisely 
defined, genetically engineered competitive in- 
hibitors may offer a wide array of useful thera- 
peutic modalities. 
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